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The homeobox transcription factors NKX2-5 and
MEIS1 are essential for vertebrate heart develop-
ment and normal physiology of the adult heart. We
show that, during cardiac differentiation, the two
transcription factors have partially overlapping ex-
pression patterns, with the result that as cardiac
progenitors from the anterior heart field differentiate
and migrate into the cardiac outflow tract, they
sequentially experience high levels of MEIS1 and
then increasing levels of NKX2-5. Using the Popdc2
gene as an example, we also show that a significant
proportion of target genes for NKX2-5 contain a bind-
ing motif recognized by NKX2-5, which overlaps with
a binding site for MEIS1. Binding of the two factors to
such overlapping sites is mutually exclusive, and this
provides a simple regulatory mechanism for spatial
and temporal synchronization of a common pool of
targets between NKX2-5 and MEIS1.INTRODUCTION
Congenital heart disease affects up to 1% of all live births in the
west and constitutes a major public health burden (Hoffman and
Kaplan, 2002). Numerous transcription factors have been shown
to play a decisive role in vertebrate heart formation (reviewed in
Bruneau, 2008). Identifying the targets of these factors and their
regulatory interactions will be amajor step toward understanding
the broader cardiac developmental program. NKX2-5 is one of
the earliest transcription factors expressed in the cardiac line-
age, and genetic studies have demonstrated that, from flies to
man, the protein has an essential function in heart development
(Biben et al., 2000; Tanaka et al., 1999). For example, NKX2-5
has been shown to regulate the size and proliferation of cardiac
precursor populations, terminal differentiation of the myocar-
dium, establishment of the ventricular conduction system, and
postnatal conduction function (Briggs et al., 2008; Jay et al.,
2004; Prall et al., 2007). In humans, mutations in the NKX2-5
gene cause congenital heart disease; haploinsufficiency resultsCin a spectrum of congenital heart disease of varying phenotypic
penetrance, which is mirrored in mouse models (reviewed in
Akazawa and Komuro, 2005).
Genome-wide occupancy profiling using chromatin immuno-
precipitation (ChIP) recently has been used to identify NKX2-5-
binding sites in both cultured cell lines and adult heart (He
et al., 2011; van den Boogaard et al., 2012); but, despite the
evident importance of NKX2-5 in heart development, no compa-
rable studies have addressed its place within the gene regulatory
network that drives cardiogenesis.
Here, we have combined genome-wide ChIP followed by
massively parallel DNA sequencing (ChIP-seq) and whole-tran-
scriptome RNA sequencing (RNA-seq) using embryonic hearts
from a mouse line that shows hypomorphic expression of
NKX2-5 and models human cardiomyopathy. This has enabled
us to identify direct targets of the NKX2-5 transcription factor
during heart development in vivo. We have found that a large
proportion of cardiac enhancers binding NKX2-5 have an over-
lapping binding site for the homeobox transcription factor,
MEIS1, indicating a regulatory interaction between these two
proteins. Our data suggest that the combination of shared
transcriptional targets, differential DNA-binding affinities, and
overlapping expression domains provides a mechanism for
spatial and temporal synchronization of a common pool of
targets between NKX2-5 and MEIS1.
RESULTS
ChIP-Seq Analysis in the Embryonic Heart Identifies
Putative Direct Targets of NKX2-5 with a Critical Role
in Heart Structure and Function
We performed ChIP with embryonic day (E)11.5 mouse embryo
hearts using an NKX2-5 antibody followed by massive, parallel
sequencing (ChIP-seq) to identify 2,610 regions enriched for
that factor (Data S1). Of these, 28 were randomly selected for
individual validation by ChIP-qPCR, all showing consistent
enrichment for NKX2-5 binding in vivo (Figure S1).
Bioinformatic analysis identified 3,313 genes flanking the
NKX2-5-binding loci (the two nearest genes for each region en-
riched in a maximum distance of 1 Mb were considered), and we
performed a computational analysis for enrichment of gene
ontology (GO) terms associated with those genes. This identifiedell Reports 13, 183–195, October 6, 2015 ª2015 The Authors 183
Figure 1. ChIP-Seq Dataset Analysis
(A) Top selected GO terms for biological processes associated with the 3,313 genes identified are shown.
(B) Regions enriched for either NKX2-5 or P300 that have been tested in vivo are plotted according to their ability to drive cardiac expression. Actives or negatives
in heart represent the percentage of enhancers able or not able to drive cardiac expression of the b-galactosidase reporter gene (p < 0.0007 according to two-
tailed Fisher’s exact test).
(C) De novo motif discovery using ChIP-MEME identified two in vivo NKX2-5-binding motifs (called selex and de novo). Selex and de novo match the UniProbe
consensus motif for NKX2-5 and MEIS1, respectively. See also Figure S3.significant enrichment of biological process related to muscle
structure development and cardiac chamber development (Fig-
ure 1A), in agreement with the known role of NKX2-5 as a cardiac
transcription factor.
To assess whether the NKX2-5-binding loci are likely to iden-
tify transcriptional enhancer regions, we compared them with
those enriched for binding of P300 in the heart at the same stage
(Blow et al., 2010). P300 is a known marker of enhancer regions
and its binding shows a significant overlap with the NKX2-5
ChIP-seq loci (78.4-fold enrichment compared to random re-
gions; see Table S1). Furthermore, by comparing both NKX2-5
and P300 datasets with regions tested for enhancer activity in
transgenic mice (as compiled in the Vista enhancer database
[Visel et al., 2007]), we found that binding of NKX2-5 was even
more reliable for predicting cardiac enhancer activity in the
E11.5 mouse heart than binding of P300 (83% versus 58%,
respectively; Figure 1B). Our data also show significant overlap
with recent studies of cardiac transcription factor binding that
have used adult heart or cardiac HL-1 cells (Blow et al., 2010;
He et al., 2011; Shen et al., 2011; van den Boogaard et al.,
2012; Table S1).
Only a small proportion of putative targets have been the sub-
ject of published studies using gene ablation that could reveal
cardiac defects. However, several already have been constitu-
tively targeted as part of the EUCOMM/KOMP initiative (Bradley
et al., 2012) and subject to comprehensive imaging at E14.5
(http://dmdd.org.uk; Mohun and Weninger, 2011). Six of the
eight genes studied in this way and present in our list of targets
show clear cardiac developmental defects, consistent with a role
in cardiogenesis. All show large ventricular septal defects asso-184 Cell Reports 13, 183–195, October 6, 2015 ª2015 The Authorsciated with aberrant connection of the great vessels to the heart
chambers (either overriding aorta [OA] or double outlet right
ventricle [DORV]). Several show abnormally thin ventricular
walls coupled with an increase in the ventricular trabecular
network (Data S2). Furthermore, selected NKX2-5-binding sites
conferred cardiac expression in a transgenic reporter assay
with zebrafish embryos (Figure S2), confirming their ability to
act as cardiac enhancers. Taken together with the bioinformatics
data, these results indicate that a large proportion of the NKX2-
5-binding regions in the embryonic heart that we have identified
are likely to be functionally relevant and associated with cardiac
development or function in vivo.
Identification of an Overlapping Binding Site Shared by
NKX2-5 and MEIS1
Sequence analysis of the 25 bp flanking the summit of each
NKX2-5-binding region was undertaken, using a de novo
motif-binding program to identify conserved DNA motifs. As
expected, the most common of these was a consensus NKX2-
5-binding site (hereafter termed ‘‘selex’’; Figure 1C, e value =
1.6e24), which matched that previously established for the
protein (NKX2-5_3436.1, uniprobe, UP00249, p = 4.71375e6)
as well as the NKX2-5-binding motifs identified in recent ChIP-
seq studies with adult heart and HL-1 cells (He et al., 2011;
van den Boogaard et al., 2012; Figure S3).
Surprisingly, the de novomotif-binding program also identified
a second common consensus (hereafter termed ‘‘de novo’’;
Figure 1C, e value = 6.5e95) that appears to be a hybrid site:
its 30 portion matches a binding motif previously identified for
the homeodomain protein MEIS1 (MEIS1_2335.1, uniprobe,
Figure 2. NKX2-5 and MEIS1 Expression Pattern
(A)Nkx2-5 andMeis1whole-mount in situ hybridization in E8.5 and E9.5 mouse embryos shows their co-expression in the anterior heart field (AHF, white arrows)
and outflow tract (OFT, arrowheads).
(B) NKX2-5 andMEIS1 immunohistochemistry on an E8.5mouse embryo (transversal section) showing colocalization in the distal OFT (bracket inmerge). Level of
section is shown with a white line in (A). AHF and heart tube (HT) are depicted in the MEIS1 immunostaining.UP00186, p = 0.000185), while the 50 is similar to the selex
(NKX2-5)-binding motif. The hybrid, de novo motif, therefore,
appears to comprise an overlapping binding site for the two tran-
scription factors. Using the Find Individual Motif Occurrences
(FIMO) software package to analyze regions immediately en-
compassing the summit of NKX2-5 binding (±25 bp), we found
that the de novo motif is present in 53.4% of binding regions,
compared with 42% for the selex motif. Only 4.6% of the regions
analyzed contained both the de novo and selex consensus
sequences. These data suggest that, in vivo, a significant pro-
portion of NKX2-5 binding on cardiac enhancers occurs via an
overlapping site shared with MEIS1.
To test the possible biological relevance of a binding site
shared by NKX2-5 and MEIS1, we first re-assessed the relative
expression patterns of the two transcription factors in the early
embryo. At E8.5 Nkx2-5 is strongly expressed in the cardiac
tube, with weaker expression in the adjacent anterior heart field
(AHF) (Figure 2A, black arrowhead and white arrow, respec-
tively). At the same stage, although Meis1 expression is unde-
tectable in much of the heart tube, it is strongly expressed in
both the AHF and in the distal part of the outflow tract (OFT),
overlapping at this stage with the expression domain of Nkx2-
5. At E9.5, expression of bothNkx2-5 andMeis1 persists strongly
in the AHF while levels of Meis1 in the distal OFT are reduced
(Figure 2A). Coexpression of MEIS1 and NKX2-5 within the distal
OFT of the heart tube at E8.5 was confirmed by immunohisto-
chemistry (Figure 2B).
Using electrophoretic mobility shift assays (EMSAs), we
confirmed that both proteins can indeed bind in vitro to the de
novo motif identified from ChIP-seq (Figure 3A; Figure S3B).
By comparing the effectiveness of the de novo and selex se-
quences to compete for binding, we established that NKX2-5
has a much higher affinity for the selex sequence compared
with the de novo motif (Figure 3B). Moreover, when tested
together, we could find no evidence for simultaneous bindingCof both proteins to the de novo sequence, rather each apparently
bound independently (Figure 3C, arrow and arrowhead). Titration
experiments demonstrated that even increasing the amount of
either protein failed to produce an additional larger-sized com-
plex (Figure 3C). Indeed, at higher concentrations of MEIS1 pro-
tein, NKX2-5 binding disappeared, (Figure 3C, compare lane 3
to lanes 10 and 11, red arrows). Interestingly, at higher NKX2-5
doses, although MEIS1 binding was inhibited, there was not
the expected further increase in NKX2-5 binding. One possible
explanation for this behavior is that, at higher concentrations,
NKX2-5 may sequester MEIS1 in a direct complex that can
bind neither site.
Our EMSA results indicate that binding of NKX2-5 and MEIS1
on the de novo motif is mutually exclusive. Consistent with this,
in a luciferase assay, individually both NKX2-5 and MEIS1 were
able to transactivate reporter expression via the de novo
sequence, but we found no evidence of synergistic activation
by the two factors (Figure 3D).
MEIS1 and NKX2-5 Successively Bind to a Popdc2
Enhancer
The Popdc2 gene (1 kb; Figure 4A, black bar) acts as an
enhancer, driving cardiac expression of a fluorescent reporter
in transgenic fish (Figure S2). A de novo DNA-binding site was
found in the region enriched for NKX2-5 binding, 110 bp
upstream of the Popdc2 transcription start site (Figure 4A). The
same region also was found to be enriched for MEIS binding
within the first branchial arch of the early embryo (Amin et al.,
2015 and see below). This sequence also drives cardiac expres-
sion in the developingmouse heart (Figure 4B). Analysis of repre-
sentative transient transgenic embryos at E9.5 showed that the
enhancer-driven transgene recapitulated normal expression in
differentiated cardiomyocytes of the cardiac tube and cardiac
precursors lying in the AHF (Froese and Brand, 2008). Expres-
sion of the transgene also was observed in the pharyngealell Reports 13, 183–195, October 6, 2015 ª2015 The Authors 185
Figure 3. NKX2-5 and MEIS1 Bind on the Same DNA Motif
(A) Electrophoretic mobility shift assay (EMSA) showing that NKX2-5 and MEIS1 bind the de novo probe (black arrowheads). Note the specific competition when
an unlabelled competitor (de novo-c) is used. White arrowheads indicate supershift when a specific antibody against the protein tested is used. Note that
competition with a mutated unlabelled probe is observed with de novo m2, but not de novo m1, when NKX2-5 protein is used. Competition with a mutated
unlabelled probe is observed with de novo m1, but not m2, when MEIS1 protein is used.
(B) The selex unlabelled probe is a better competitor than the de novo unlabelled probe when used with selex or de novo radioactive probes. Black arrowhead
indicates NKX2-5 probe complex.
(C) EMSA showing the absence of any supershift when both NKX2-5 and MEIS1 proteins are added in increasing amounts. Increasingly prominent band slightly
above the position of the MEIS1 complex in lanes 10 and 11 (indicated with *) is detectable in the presence of MEIS1 alone in lane 3, and its apparent increase
simply reflects the increase in overall MEIS1 concentration in the titration experiment. Black arrow and black arrowhead indicate MEIS1 and NKX2-5 binding on
the de novo probe, respectively. Note the disappearance of NKX2-5 binding in lanes 10 and 11 at higher concentrations of MEIS1 (red arrow).
(D) NKX2-5 and MEIS1 activate the de novo fragment cloned in pGL3 in 3T3 cells. Note the absence of synergistic activation. The graph shows relative luciferase
reporter activity normalized to reporter construct alone. Average of three independent experiments is shown. Error bars represent the SEM.arch and the proepicardium (Figure 4B, asterisk and white ar-
row), as observed for the Popdc2 gene itself (Froese and Brand,
2008).Meis1 expression also was observed in these tissues, but186 Cell Reports 13, 183–195, October 6, 2015 ª2015 The Authorsno expression of Nkx2-5 could be detected (data not shown).
Moreover, Popdc2 RNA expression was downregulated in
Nkx2-5-null hearts at E9.0 compared with controls (Figure S4A).
Figure 4. NKX2-5 and MEIS1 Successively Bind a Popdc2 Enhancer
(A) ChIP-seq trace at the Popdc2 locus for the two experiments carried out (s1 and s4). Black bar indicates the region found enriched for NKX2-5 binding and
tested in transgenic mice (see below).
(B) Representative image of a mouse transgenic embryo at E9.5 showing that the Popdc2 enhancer is reproducing endogenous Popdc2 gene expression in the
heart and AHF. Four independent embryos expressed the reporter gene of the seven PCR-positive embryos for the transgene. Planes a and b represent
transversal sections as indicated on the whole mount. Asterisk shows pharyngeal arches, white arrow in plane b shows proepicardium, and white arrowhead
indicates expression of the transgene in the AHF.
(C) ChIP analysis carried out with chromatin purified from E9.5 AHF and heart with either MEIS1 or NKX2-5 antibodies. Representative results of qPCR analysis
with primers against the region of the Popdc2 promoter enriched for NKX2-5 binding are shown. Relative enrichment is presented over a negative control region in
the gamma-crystallin gene (gcrys). *p < 0.05, **p < 0.001 according to a two-tailed Student’s t test.
(D) Venn diagram depicting the overlap between NKX2-5- and MEIS-enriched regions. In red are the number of those overlapping regions corresponding to the
overlapping binding site.
(E) Top selected GO terms were identified with GREAT for biological processes associated with the genes associated with either the NKX2-5- or NKX2-5/MEIS-
bound regions.
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A similar, though less profound effect was observed at E11.5 in
hearts that are hypomorphic for NKX2-5 expression (Figure S4B).
These data indicate that NKX2-5 plays a major role in regulating
the expression of Popdc2.
To examine directly the relative binding of MEIS1 and NKX2-5
in vivo, we performed ChIP experiments on the Popdc2
enhancer using chromatin from samples prepared from the
AHF and heart of E9.5 embryos. NKX2-5 binding on the Popdc2
enhancer was found to be much stronger in chromatin extracted
from the embryonic heart compared to the adjacent AHF (Fig-
ure 4C). Conversely, MEIS1 bound more strongly in chromatin
extracted from the AHF rather than the heart. The relatively low
level of enrichment found for MEIS1 in the heart and NKX2-5 in
the AHF parallels the low level of expression of these factors
within the respective tissues (Figure 2). These results indicate
that MEIS1 binding on the Popdc2 enhancer predominates in
the AHF, while NKX2-5 binding predominates in the heart.
To assess whether other gene enhancers containing the de
novo DNA-binding motif showed similar tissue-specific differen-
tial binding, we tested four such genomic enhancer regions iden-
tified by ChIP-seq for Nkx2-5 in the embryonic heart (Myocardin,
Lpar3, Cadm1, and Gja1/Hsf2 loci; Data S3). All showed a
pattern of enrichment for MEIS binding in the AHF and NKX2-5
binding in the heart, suggesting that this behavior is likely to be
shared by many of the genomic regions harboring the de novo
site identified by our ChIP-seq study.
MEIS1 and NKX2-5 Bind to the Same Regions In Vivo
It is well established that the mesodermal core of the first and
second branchial arches contains cardiac progenitor cells,
which migrate from this region to populate the OFT and cham-
bers of the developing heart (Lescroart et al., 2010). A recent
study has documented MEIS genomic occupancy in the bran-
chial arches (Amin et al., 2015), enabling us to compare on a
genome-wide basis the loci binding MEIS in the AHF with those
binding Nkx2-5 in the heart.
Strikingly, 765 of the 2,610 regions enriched for NKX2-5 bind-
ing (29.31%) also were identified by MEIS binding in the first
branchial arches. A similar overlap was evident with the second
branchial arches (787 regions or 30.15%; Table S1; Figure 4D).
This represents a 50-fold enrichment compared to random
(Table S1), lending further support to the suggestion that the suc-
cessive binding of MEIS and NKX2-5 that we initially observed
for Popdc2 is shared by an entire subset of cardiac enhancers.
In an attempt to discriminate between the occurrence of
closely associated and directly overlapping binding sites for
MEIS1 and NKX2-5, we repeated this analysis but restricted
the comparison to a region of ±6 bp around the summit of the
binding peaks identified in the different datasets. Under these
conditions, 105 binding sites overlapped between NKX2-5 and
MEIS in the first branchial arch and, therefore, most likely repre-
sent direct overlap of the two binding sites. Comparable analysis
yielded 79 common, overlapping sites in the second branchial
arch. These results suggest that a significant fraction of MEIS
and NKX2-5 interaction in vivo is mediated by a direct site
overlap.
Interestingly, GO analysis suggests that the subset of genes
regulated by both MEIS1 and NKX2-5 may have a distinct188 Cell Reports 13, 183–195, October 6, 2015 ª2015 The Authorsfunction. The 1,845 regions that bound NKX2-5 alone are asso-
ciated with genes involved with cardiac muscle structure and
development; in contrast, the 765 regions that bound both
MEIS1 and NKX2-5 are primarily associated with genes involved
with DNA metabolic processes, signaling, and cell-cycle regula-
tion (Figure 4E). No significant difference was evident in GO
terms when we divided the 765 between those showing the
closest association of MEIS and NKX2-5 binding (105) and the
rest (660).
Identification of Putative Direct Targets for NKX2-5
Reveals a Dual Role as Both Activator and Repressor
Comparison of ChIP-seq and transcriptomic data provides a
powerful way to identify likely transcriptional targets by identi-
fying those that both bind the transcription factor and are dysre-
gulated in its absence (Sakabe et al., 2012). For NKX2-5, this
strategy is precluded since Nkx2-5 knockout embryos die early
(E9.5) due to failure of heart development (Biben et al., 2000;
Tanaka et al., 1999). As an alternative, we took advantage of a
previously generated mouse model showing hypomorphic
expression of NKX2-5 (Prall et al., 2007; Stanley et al., 2002),
enabling us to test the effect of reduction, rather than absence,
of NKX2-5 expression. Mendelian analysis showed no change
in mortality of this hypomorphic line at E11.5, E12.5, and
E13.5. However, by E14.5, only 60% of the expected number
of hypomorphic embryos were recovered (Table S2) and only a
few hypomorphic embryoswere obtained at birth (none surviving
past weaning). Consistent with these observations, the structure
of the hypomorph heart showed profound abnormalities by
E14.5, including thinning of ventricular walls, the presence of
large ventricular septal defects, and signs of hypertrabeculation
(Figure 5A).
In contrast, at E11.5, the hearts of hypomorphic embryos were
morphologically indistinguishable from those of sibling controls,
and we therefore used this stage for transcriptome analysis.
RNA-seq comparing E11.5 hypomorphic mutant and control
hearts identified statistically significant alterations in the expres-
sion of 1,492 genes (Data S4). By using this to filter the ChIP-seq
data, we were able to identify 309 genes as high-probability,
direct targets of NKX2-5 (Figure 5B). GO term analysis of these
indicated that the categories of biological processmost enriched
are related to cell signaling and differentiation (Figure 5C, p <
0.002 for all categories). Furthermore, the most enriched biolog-
ical pathways are related to signaling (Figure S4D). Interestingly,
of the 309 identified genes, 172 (55.6%) were downregulated
and 137 (44.4%) were upregulated, suggesting that NKX2-5
functions both as a transcriptional activator and as a repressor
(Figure 5B).
One role of NKX2-5 suggested by studies of the null mutant is
in the regulation of cardiac chamber development (Dupays et al.,
2005; Tanaka et al., 1999). We tested this hypothesis by classi-
fying the direct NKX2-5 targets identified in our studies accord-
ing to their expression pattern in the hypomorphic heart, taking
advantage of previous studies that examined genes differentially
expressed between chamber and non-chamber myocardium
at E10.5 (Horsthuis et al., 2009). This enabled us to distinguish
between genes restricted to the atrioventricular canal (AVC)
or working myocardium, compared with those more broadly
Figure 5. NKX2-5 Acts as an Activator and a Repressor
(A) Four-chambered view comparing hearts from hypomorphic embryos to controls using high-resolution episcopic microscopy. At E11.5, no obvious
morphological defect can be detected. At E14.5, hearts from hypomorphic embryos present ventricular septal defect (star) and thinning of the compact layer
ventricular free wall (compare red size bar).
(B) Venn diagram depicts the overlap between NKX2-5-enriched region-associated genes (white) and genes downregulated (gray) and upregulated (red) in the
heart of hypomorphic embryo.
(C) Most enriched biological processes in the direct target genes list are shown.
(D) Direct targets are categorized by expression pattern as AVC specific or working myocardium. n.s., non-significant; **p < 0.002, *p < 0.0489 according to two-
tailed Fisher’s exact test. See also Figure S4D.expressed (and classified as ‘‘pan-myocardial’’). Those ex-
pressed in the AVC or throughout the myocardium were upregu-
lated or downregulated in the hypomorph in approximately
equal proportions (Figure 5D). In contrast, those NKX2-5 targets
whose expression was restricted to the chamber myocardium
were predominantly downregulated in the mutant (Figure 5D),
consistent with an essential role for NKX2-5 in promoting cardiac
chamber formation.
NKX2-5 Directly Represses the Expression of Tnnt3
and Tnni2 in the Atria
Our finding that almost half of the putative direct targets of
NKX2-5 identified by intersection of ChIP-seq and transcrip-
tomic data are upregulated in the hypomorph is striking, since
most previous studies have focused on the role of NKX2-5 as a
transcriptional activator (Tanaka et al., 1999). One noteworthy
example of negative regulation revealed by our study is associ-
ated with binding of NKX2-5 to a region 1 kb upstream of the
Lsp1 gene transcription start site (Figure 6A) harboring a selexCDNA-binding site (referred as Tnni2-Tnnt3-enh). Lsp1 showed
no detectable expression in cardiomyocytes at E11.5, its expres-
sion being restricted to a population of cardiac fibroblasts and
remaining unchanged in the hypomorph at E14.5 (Figure 6B).
However, the two skeletal troponin T genes, Tnni2 and Tnnt3,
are located 38 kb upstream and 17 kb downstream, respectively,
of the Lsp1-associated NKX2-5-binding region. Furthermore,
reduced expression of NKX2-5 expression in the hypomorph
heart resulted in upregulation of both troponin genes in the
myocardium at E11.5 and E14.5 (Figure S5A; Figure 6B). That
the expression of the two skeletal troponin isoforms was
restricted to the atrial myocardium of the developing heart indi-
cates further levels of control that distinguish atrial from ventric-
ular myocardium.
We investigated the putative repressor function of NKX2-5
using short hairpin RNA technology to knock down NKX2-5
expression in the HL-1 cardiac cell line. Cells stably transfected
with shNkx2-5 showed a significant decrease in NKX2-5 protein
expression (Figure S5B). Using these, we tested the effect ofell Reports 13, 183–195, October 6, 2015 ª2015 The Authors 189
Figure 6. NKX2-5 Represses Cardiac Expression of Fast Troponin Isoforms
(A) ChIP-seq trace at the repressed Lsp1 locus for the two experiments carried out (s1 and s4). Black bars indicate regions found enriched for NKX2-5.
(B) In situ hybridization on sections of E14.5 control and hypomorph hearts, using probes for Tnni2, Tnnt3, and Lsp1. Note the upregulation of Tnni2 and Tnnt3
signals in the hypomorph atria (black arrows). See also Figure S5A.
(legend continued on next page)
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NKX2-5 knockdown on the expression of a luciferase reporter
carrying the 461-bp Tnni2-Tnnt3-enh fragment (Figure 6C).
Luciferase activity was significantly enhanced in HL-1 cells
deficient for NKX2-5 compared with controls, but unchanged
after mutation of the selex DNA-binding site (Tnni2-Tnnt3-enh-
mut; Figure 6C). Furthermore, co-transfection with increasing
amounts of an NKX2-5 expression plasmid progressively
repressed luciferase reporter activity, but had no effect after
mutation of the selex site (Figure 6D). Together, these results
demonstrate the ability of NKX2-5 to repress activity from the
Tnni2-Tnnt3-enh enhancer sequence.
DISCUSSION
This study describes the genome occupancy of NKX2-5 during
a critical phase of cardiac differentiation in the mouse embryo.
Our data show that NKX2-5 binding is an efficient predictor of
cardiac enhancer location and even more effective than the
binding of P300 at the same stage (Blow et al., 2010).
NKX2-5 Can Bind through an Overlapping Site with
MEIS1 In Vivo
Our analysis demonstrates that, in vivo, not only is NKX2-5 able
to bind to the conventional NKX2-5-binding motif, but it also
binds to a related sequence that overlaps with the DNA-binding
site for the transcriptional cofactor MEIS1. Comparison of MEIS
binding in cardiac precursor tissue of the branchial arches with
NKX2-5 in the heart shows that those two factors bind on a
common group of enhancers during cardiac differentiation.
A potential role for MEIS proteins as regulators of cardiomyo-
cyte differentiation has been suggested previously (Paige et al.,
2012; Wamstad et al., 2012). Consistent with this, in the mouse
embryo, ablation of MEIS1 results in prenatal death, the null em-
bryos having severe developmental abnormalities (Azcoitia et al.,
2005; Hisa et al., 2004), including ventricular septal defects and
an overriding aorta (Stankunas et al., 2008). These are reminis-
cent of the phenotype found in embryos showing hypomorphic
levels of NKX2-5 (Figure 5A; Prall et al., 2007). Recently, MEIS1
also has been shown to regulate postnatal cardiomyocyte pro-
liferation (Mahmoud et al., 2013). Furthermore, genome-wide
association studies have linked bothNkx2-5 andMeis1 to abnor-
malities in the PR interval, a region of the electrocardiogram
(ECG) that reflects atrial and atrioventricular nodal conduction
(Pfeufer et al., 2010; Smith et al., 2011). Given that defects in
conduction are associated with mutations in NKX2-5 in both hu-
man and mouse models, our finding that the two factors share a
common set of gene targets might account for these results.
We have found that, in the early mouse embryo heart, MEIS1 is
co-expressed with NKX2-5 protein in the AHF and the OFT.
Levels of MEIS1 are higher in the AHF and decrease through
the outflow toward the ventricular myocardium. NKX2-5 shows
a reciprocal pattern of early expression, with levels in the myo-
cardium being considerably higher than those found in the AHF.(C) Tnni2-Tnnt3 enhancer (Tnni2-Tnnt3-enh) activity in control and NKX2-5-defic
(D) Co-transfection of Tnni2-Tnnt3-enh with an increasing quantity of Nkx2-5-ex
reporter vector is unaffected by Nkx2-5 overexpression in HL-1 cells. Only sign
t test.
CIn a recent study, Amin et al. (2015) analyzed the genomic
occupancy of MEIS factors in the branchial arches, identifying
a very large number (>60,000) of binding sites. They noted
that the top 1% of MEIS-binding regions were associated with
genes involved in skeletal muscle development (see Figure 5F
in Amin et al., 2015). Comparison with the NKX2-5-binding
data we have obtained now reveals that a significant fraction
of NKX2-5-dependent cardiac enhancers harbors an overlap-
ping MEIS site.
The developmental period during which cells migrate from the
AHF into the developing heart coincides with a transition from
cardiac progenitors to differentiated cardiomyocytes, resulting
in many well-documented changes in gene expression (Domian
et al., 2009; Wamstad et al., 2012) and cell cycling (Cai et al.,
2005; van den Berg et al., 2009). These coincide with the period
over which we identify the switch in expression from MEIS1 to
NKX2-5. It is, therefore, tempting to speculate that the subgroup
of MEIS1-regulated genes that shows overlapping binding by
NKX2-5 is associated with these differentiation changes.
Consistent with this, we found that 79 of the genes associated
with those 765 regions are in common with target genes associ-
ated with enhancers containing the MEIS1 motif in differentiated
cardiac embryonic stem cell (Wamstad et al., 2012). Further-
more, using previously published data that identifies genes en-
riched in the AHF compared to the heart and vice versa (Domian
et al., 2009), we found that 51 of the genes associated with
NKX2-5/MEIS-bound regions are AHF enriched, while 76 are
from the heart-enriched class (see Figure S4C). Many of these
genes have well-described expression patterns and have been
associated with changes in DNA metabolism, cell cycling,
and cell signaling (e.g., Tbx20, myocardin, Cdh2, Wnt11, and
Wnt2), which are consequent upon cardiac progenitor differenti-
ation. Together, these results suggest that enhancers binding
both MEIS1 and NKX2-5 constitute a functionally distinct class
of genes compared with those regulated by MEIS1 alone.
Given that early heart growth largely results from the addition
of cells from the AHF to the poles of the heart (Cai et al., 2003;
Kelly, 2012), our data suggest that a significant portion of
NKX2-5-binding regions are regulated through successive
binding first by MEIS1 and later by NKX2-5 as differentiation
(and cardiac morphogenesis) proceeds. Interestingly, a similar
temporal pattern of expression of those factors is found during
embryonic stem differentiation into beating cardiomyocytes
(Wamstad et al., 2012). In such stem cell cultures, cardiomyocyte
precursors express high levels of Meis1 RNA and relative low
levels of the Nkx2-5 transcript. However, when such precursors
differentiate into cardiomyocytes, Meis1 RNA expression de-
creases and Nkx2-5 RNA expression increases (see Figure S2
in Wamstad et al., 2012).
Transcriptional regulation in a similar manner through shared
binding sites and overlapping but distinct spatial patterns
of transcription factor expression already has been described
during cardiogenesis, from studies of the growth factor FGF10.ient HL-1 cells is shown.
pressing vector shows a decrease of reporter activity. Tnni2-Tnnt3-enh-mut
ificant changes are indicated. *p < 0.05 according to a two-tailed Student’s
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An Fgf10 enhancer possesses a shared binding site for NKX2-5
and the transcription factor ISL1. Fgf10 is activated in the AHF by
ISL1, but subsequently repressed by NKX2-5 as cells of the AHF
are added to the heart tube (Watanabe et al., 2012). Our data
now suggest a similar regulatory mechanism with MEIS1 and
NKX2-5, and we speculate that the presence of overlapping
transcription factor binding sites in gene enhancers might
therefore be of broader significance during development. For
gene enhancers containing such overlapping binding sites,
distinct regional patterns of transcription factor expression could
combine with cell migration to achieve complex patterns of
spatiotemporal regulation.
Common targeting of a set of genes by MEIS1 and NKX2-5
could facilitate several different regulatory mechanisms underly-
ing cardiac differentiation. For example, preferential binding by
MEIS1 within the AHF could act to prevent activation of a set
of cardiac differentiation genes normally activated by NKX2-5;
these genes subsequently would become activated as AHF cells
are added to the cardiac tube andMEIS1 is replaced by NKX2-5.
An alternative possibility is a role for MEIS1 in activating genes
that are part of a cardiac progenitor state program in the AHF.
As cardiac precursors integrate into the developing heart,
replacement of MEIS1 by NKX2-5 would serve to repress these
genes and, thereby, allow cardiomyocyte differentiation. Consis-
tent with this latter model, Nkx2-5mutants have been reported to
show upregulation of progenitor signature genes in the AHF and
abnormal persistence of their expression in differentiating myo-
cytes (Prall et al., 2007). Furthermore, our results show that there
is a clear difference between biological processes associated
with genes showing NKX2-5 binding and those regulated by
both NKX2-5 and MEIS. The former are specific to the differen-
tiated cardiac state, whereas the latter are related to other
biological processes (metabolism, signaling, and cell-cycle
regulation), which perhaps reflects their role in a cardiac progen-
itor gene program.
A third possibility is suggested by accumulating evidence that
gene enhancers can interact with pioneer transcription factors at
early stages of development before the target genes are even
transcribed (Kathiriya et al., 2015). For example, in the branchial
arches, HOXA2 and MEIS binding largely overlaps and it has
been suggested that MEIS binding functions to create an acces-
sible platform recognized by HOXA2 (Amin et al., 2015). Simi-
larly, in the mouse embryo trunk, Hox target sequences have
been shown to strongly associate with MEIS factors (Penkov
et al., 2013). Perhaps when both MEIS1 and NKX2-5 activate a
common set of enhancers, MEIS1 establishes a ground state
that maintains competence for eventual activation by NKX2-5
at the appropriate stage of cardiac differentiation.
Genome-wide studies of NKX2-5-binding sites in the adult
mouse heart show no statistically significant enrichment for the
de novo binding motif (van den Boogaard et al., 2012; data not
shown), in contrast to our findings for the E11.5 embryonic heart.
This may reflect the exclusive developmental role of the MEIS/
NKX2-5 combination, but it also could be accounted for by the
nature of ChIP studies themselves. Since noMEIS1 is expressed
in the embryonic heart, enhancers containing the de novo bind-
ing site will be recovered by ChIP using an NKX2-5 antibody.
In contrast, as the adult heart expresses MEIS1, this factor will192 Cell Reports 13, 183–195, October 6, 2015 ª2015 The Authorscompete with NKX2-5 for binding onto the de novo motif. Prefer-
ential binding by MEIS1 in vivo (comparable with that we de-
tected in vitro) would reduce or abolish recovery of sequences
containing the de novo consensus by NKX2-5 ChIP.
NKX2-5 Represses the Muscle Fast Fiber Phenotype
NKX2-5 previously has been shown to be capable of acting as a
transcriptional repressor (Prall et al., 2007). Our study provides
evidence of how widespread such a role may be during develop-
ment, with nearly 50% of the putative direct targets identified in
the embryonic heart likely to be regulated by NKX2-5 in this
manner.
Our study of the NKX2-5 hypomorph embryos revealed an
unexpected role for NKX2-5 that is notable in several ways.
NKX2-5 apparently regulates skeletal muscle fiber type and
does so via repression of two skeletal fast isoforms of troponin.
Individual isoforms show quantitative differences in the calcium
activation of contraction that can affect cardiac muscle perfor-
mance and heart contraction (Huang et al., 2008; Parmacek and
Solaro, 2004). The strong upregulation of Tnnt3 and Tnni2 that
occurs in the developing atria of the NKX2-5 hypomorph is
likely, therefore, to result in alteration of contractile perfor-
mance, through its impact on myofibrillar calcium activation.
The morphological abnormalities seen in the hypomorph hearts
at E14.5 included changes (wall thinning and atrial distension)
indicative of compromised cardiac function. Our findings indi-
cate that this might not simply be an indirect and cumulative
consequence of cardiac dysfunction in the hypomorph; it may
in fact be largely driven by a direct impact of reduced NKX2-5
levels on atrial myofibrillar composition. Interestingly, a similar
upregulation of fast skeletal troponin isoforms has been
observed in several models of cardiac failure induced by loss
of either histone deacetylases or the polycomb repressive com-
plex 2 (Delgado-Olguı´n et al., 2012; He et al., 2012; Montgomery
et al., 2007).
EXPERIMENTAL PROCEDURES
Animals
All animal work was carried out in accordance with the UK Animals (Scientific
Procedures) Act 1986 and with the approval of the MRC National Institute
of Medical Research Ethical Review Panel. Genotyping of the transgenic
mouse lines Nkx2-5-IRES-Cre and Nkx2-5-gfp has been described previously
(Prall et al., 2007).
ChIP Assay and Real-Time qPCR Analysis
Please refer to the Supplemental Experimental Procedures.
Sequencing and Peak Calling
Libraries were prepared with 10 ng immunoprecipitated DNA or input.
Samples were sequenced on the Genome Analyzer IIx platform, and ChIP-
seq reads were aligned to the mm9 genome assembly using BOWTIE. Peak
calling was done using MACS1.4. Please refer to the Supplemental Experi-
mental Procedures for more details.
Sequence and Gene Analysis
All enriched GO categories were determined using the programs GeneCoDis3
(Carmona-Saez et al., 2007) and GREAT for peak-associated genes. De novo
motif identification was carried out using 50 bp around the summit of the
peak of the top 1,033 regions using MEME-ChIP (Machanick and Bailey,
2011). Enhancer coordinates were found in the VISTA Enhancer Browser
(Visel et al., 2007) and compared to our set using Galaxy (Giardine et al., 2005).
For comparison of the different ChIP-seq datasets, 10,000 random sets were
generated and compared using pybedtools (Dale et al., 2011; Quinlan andHall,
2010).
Motif distribution and overlap of the different NKX2-5motifs among the iden-
tified peaks were done with FIMO using default parameters and the matrices
identified with MEME.
Expression array data (GEO: GSE13614) used to analyze working myo-
cardium genes versus atrio-ventricular genes were analyzed using Limma
at Geo2r (http://www.ncbi.nlm.nih.gov/geo/geo2r/). The p values were
adjusted for multiple testing using the Benjamin and Hochberg test, and
transcripts were identified as differentially expressed if the adjusted p value
was <0.01.
The region overlap between the NKX2-5 and MEIS dataset was determined
using Galaxy (Goecks et al., 2010).
RNA-Seq
The E11.5 embryonic hearts from the hypomorphic NKX2-5 line were
dissected and stored in RNAlater (QIAGEN). After genotyping, three control
and three hypomorphic samples were selected for total RNA extraction using
Trizol and purified on RNeasy columns (QIAGEN). Total RNA was converted
to a library of templates suitable for high-throughput DNA sequencing
using the Truseq kit (Illumina). Templates were sequenced using the Illumina
Genome Analyzer IIx platform. Sequence reads were aligned to the mm9
genome with TopHat. Mapped reads were analyzed using the Avadis NGS
package (Strand Scientific Intelligence; AC test fold change R1.5).
EMSA
Recombinant proteins were synthesized using a coupled transcription-
translation system (Promega TnT T7/SP6 kit) and incubated with 0.5 ng radio-
labelled oligonucleotide probe in binding buffer (20 mM Tris [pH 7.6], 75 mM
KCl, 0.25 mg/ml, 1 mM DTT, and 10% glycerol) at room temperature for
10min. For competition experiments, the excess of unlabelled oligonucleotide
probes was added and incubated for 10 min prior to the addition of radiola-
belled oligonucleotide probes. Binding reactions were analyzed on 6% 0.53
Tris-borate-EDTA (TBE) polyacrylamide gels electrophoresed at 150 V; gels
were dried prior to detection of signal by autoradiography.
In Situ Hybridization
RNA in situ hybridizations were performed as described previously (Dupays
et al., 2005). Tnnt3, Tnni2, and Lsp1 RNA probes were synthesized fromwhole
IMAGE clones 3594256, 1448494, and 3488528, respectively.
Immunohistochemistry
Immunohistochemistry was performed as described previously (Dupays et al.,
2009) with NKX2-5 (Santa Cruz Biotechnology) and MEIS1 (Abcam, ab19867)
antibodies.
High-Resolution Episcopic Microscopy Imaging
Embryos were embedded and processed for imaging as described previously
(Mohun and Weninger, 2011).
Transgenic Fish Experiments
Mouse DNA fragments were tested in vivo using the tol2 system (Allende et al.,
2006; Fisher et al., 2006). Briefly, 1 kb amplified PCR product flanking the
NKX2-5-enriched region was cloned in pCR8/GW/TOPO vector (Invitrogen)
and subcloned into pGW_cfosGFP vector. Embryos were scored for GFP
heart expression 48 hr after co-injection with Tol2 transposase into one-cell-
stage zebrafish embryos.
Transgenic Mouse Experiments
The Popdc2 region tested previously in fish was subcloned in an hsp68-LacZ
reporter gene. Transient transgenic mouse embryos were generated by the
Procedural Services Section at The Francis Crick Institute Mill Hill Laboratory
by standard pronuclear microinjection techniques.CACCESSION NUMBERS
The accession number for the ChIP-seq and RNA-seq data reported in this pa-
per is GEO: GSE44576.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, two tables, and four data files and can be found with this article
online at http://dx.doi.org/10.1016/j.celrep.2015.08.065.
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